Indian pharma can't afford to miss governance bus amid growth focus

Regulatory clampdowns and legislative changes are likely to expose the governance fault lines of the companies in the sector. Investors in the sector need to be cognisant of these emerging risk factors.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/Rigr5VU
via IFTTT